29 search results for: COPD

interactivity

Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

5 min

Pulmonology

Learn about the disease burden and heterogeneity of chronic obstructive pulmonary disease (COPD).

interactivity

Lung Function Decline: Why it Matters and What’s at Stake for Patients

5 min

Pulmonology

Understand the drivers of lung function decline in chronic obstructive pulmonary disease (COPD), including chronic inflammation, key risk factors, and the impact on patient well-being .

expert video

Exacerbations Lead to Worsening Lung Function

2 min

Type 2 Inflammation

Dr. Mario Castro discusses how COPD exacerbations can predict future exacerbations and lead to progressive lung function loss in COPD patients.

expert video

ERS 2024 | IL-33 A Promising Target

7 min

Pulmonology

Professor Klaus Rabe presents the latest clinical data on current and emerging biologic therapies targeting IL-33 in COPD.

expert video

ERS 2024 | What Do We Know About IL-33 Genetics?

14 min

Pulmonology

Dr. Stephanie Christenson examines the genetic and environmental factors influencing IL-33 expression and activity in COPD, highlighting the complex interplay between genetics, smoking, and disease pathogenesis.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: QatarChange country/region